Systematic review of psilocybin for depression: how it may work and how well it works

The question

What is known about how psilocybin might act on the brain, and how well does it work as a treatment for depression?

What they did

The authors searched three research databases (PubMed, Web of Science and ScienceDirect) for studies published between January 2021 and March 2026 on psilocybin’s antidepressant mechanisms and clinical effects. They followed PRISMA reporting guidelines and registered the review plan in advance with PROSPERO. Of 949 records screened, 46 original studies were included. Findings were grouped into molecular, cellular, brain-circuit and clinical levels.

What they found

The authors report that psilocin, the active compound the body makes from psilocybin, may act through several routes: activation of the 5-HT2A serotonin receptor, BDNF-TrkB signalling (a pathway linked to brain cell growth), new cell growth in the hippocampus, and changes in the default mode network, a set of brain regions active during self-focused thought. On the clinical side, they report that single or limited-dose psilocybin, particularly 25 mg, was linked to rapid and sustained symptom relief in treatment-resistant depression, with effects the authors describe as comparable or superior to the antidepressant escitalopram. No pooled effect sizes or total participant numbers were given in the abstract.

The fine print

This is a narrative synthesis, not a meta-analysis, so no combined numbers, effect sizes or confidence intervals are reported. Much of the mechanism evidence comes from laboratory and animal work that cannot be directly applied to people. The abstract does not say how many people took part in the clinical trials reviewed, how long they were followed, or how study quality and risk of bias were assessed. Psilocybin trials are also hard to blind, since participants usually know if they received an active dose. This summary is based on the abstract only.

What it means

The review pulls together biological and clinical evidence suggesting psilocybin can rapidly reduce depression symptoms in trials, but without pooled data or quality ratings in the abstract, its conclusions should be read as a broad overview rather than firm proof.

Evidence grade: Low. A systematic review that summarizes findings narratively, mixes laboratory mechanism studies with clinical trials, and does not pool results statistically.

This summary is based on the study’s published abstract.